Literature DB >> 1894300

Prevalence of rheumatic fever and rheumatic heart disease in school children in a rural community of the hill region of Nepal.

U K Shrestha1, T N Bhattarai, M R Pandey.   

Abstract

A survey of school children aged 5 to 16 years living in a rural community of the hill region of Nepal, situated about 15-22 km outside Kathmandu city, was conducted to determine the prevalence of rheumatic fever (RF) and rheumatic heart disease (RHD). Of the 4,816 eligible children enrolled in the selected schools, 4,452 (92.4%) were examined. WHO expert committee criteria (1966) was used for the diagnosis and classification of rheumatic fever. Chest x-ray, electro-cardiography, echocardiography and Doppler study were done in all suspected cases of rheumatic heart disease. Six cases of RHD (1 pure mitral stenosis, 3 mitral regurgitation and 2 combined mitral stenosis and regurgitation) were identified giving overall prevalence rate of 1.35 per thousand. No case with active rheumatic fever could be identified. This is the first study on prevalence of RF/RHD in Nepal. The prevalence rate is lower than that reported from neighbouring countries.

Entities:  

Mesh:

Year:  1991        PMID: 1894300

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  3 in total

Review 1.  Echocardiographic screening for subclinical rheumatic heart disease remains a research tool pending studies of impact on prognosis.

Authors:  Liesl Zühlke; Bongani M Mayosi
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

2.  Tackling cardiovascular health and disease in Nepal: epidemiology, strategies and implementation.

Authors:  Abhinav Vaidya
Journal:  Heart Asia       Date:  2011-01-01

3.  Epidemiological survey of rheumatic heart disease among school children in the Shimla Hills of northern India: prevalence and risk factors.

Authors:  J S Thakur; P C Negi; S K Ahluwalia; N K Vaidya
Journal:  J Epidemiol Community Health       Date:  1996-02       Impact factor: 3.710

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.